Skip to main content

Advertisement

SpringerLink
Log in

Clostridium difficile-associated enteric disease

  • Published:
Current Infectious Disease Reports Aims and scope Submit manuscript

Abstract

Clostridium difficile was identified as the putative agent of antibiotic-associated pseudomembranous colitis in 1978 and is now recognized as the major identifiable cause of antibioticassociated diarrhea. This microbe causes a spectrum of enteric disease ranging from nuisance diarrhea to life-threatening colitis. Risk factors include increasing age, exposure to antibiotics, colonization or acquisition of toxin-producing strains of C. difficile, and lack of circulating antibody to C. difficile toxin A. Detection is relatively simple by stool assay for C. difficile toxin—usually an enzyme immunoassay that will detect toxin A and B. Most nonsevere cases will respond with discontinuation of the implicated antibiotic. More severe cases require metronidazole and supportive care. The major complications include ileus, toxic megacolon, relapsing disease after antibiotic treatment, and nosocomial epidemics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Khan MY, Hall WH: Staphylococcal enterocolitis: treatment with oral vancomycin. Ann Intern Med 1966, 65:1.

    PubMed  CAS  Google Scholar 

  2. Tedesco FJ, Barton RW, Alpers DH: Clindamycin-associated colitis: a prospective study. Ann Intern Med 1974, 81:429.

    PubMed  CAS  Google Scholar 

  3. Bartlett JG, Chang TW, Gurwith M, et al.: Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med 1978, 298:531.

    Article  PubMed  CAS  Google Scholar 

  4. Karlstrom O, Fryklund B, Tullus K, Burman LG: A prospective nationwide study of Clostridium difficile-associated diarrhea in Sweden. Clin Infect Dis 1998, 26:141–145.

    PubMed  CAS  Google Scholar 

  5. Safdir N, Maki DG: The commonality of risk factors for nosocomial colonization and infection with antibiotic resistant S. aureus, enterococcus, gram negative bacilli, C. difficile and Candida. Ann Intern Med 2002, 136:834–844. The authors showed that the risk factors for C. difficile complications were similar to those for infections by other infamous nosocomial pathogens—vancomycin-resistant Enterococcus, methicillin-resistant S. aureus, Candida, and so forth.

    Google Scholar 

  6. Bartlett JG: Antibiotic-associated diarrhea. N Engl J Med 2002, 346:334–339. Recent review that shows the methods to distinguish C. difficile from other causes of antibiotic-associated diarrhea. The most common cause is attributed to changes in the colonic flora that change carbohydrate and bile acid metabolism.

    Article  PubMed  Google Scholar 

  7. Taylor NS, Thorne G, Bartlett JG: Comparison of two toxins produced by Clostridium difficile. Infect Immun 1981, 34:1036.

    PubMed  CAS  Google Scholar 

  8. Phelps CJ, Lyerly D, Johnson J, Wilkins TD: Construction and expression of the complete Clostridium difficile toxin A gene in Escherichia coli. Infect Immun 1991, 59:150.

    PubMed  CAS  Google Scholar 

  9. Riegler M, Sedivy R, Pothoulakis C, et al.: Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. J Clin Invest 1995, 95:2004–2011.

    Article  PubMed  CAS  Google Scholar 

  10. Johnson S, Kent SA, O’Leary KJ, et al.: Fatal pseudomembranous colitis associated with a variant Clostridium difficile strain not detected by toxin A immunoassay. Ann Intern Med 2001, 135:434–438. The authors present a case of C. difficile-associated PMC that was fatal because it was never treated. The problem was that toxin assays were always negative for a case involving a strain that produced only toxin B and the laboratory used an EIA that detected only toxin A.

    PubMed  CAS  Google Scholar 

  11. Saif N, Brazier JS: The distribution of Clostridium difficile in the environment of South Wales. J Med Microbiol 1996, 45:133–137.

    Article  PubMed  Google Scholar 

  12. Kim KH, Fekety R, Botts DH, Brown D: Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis. J Infect Dis 1981, 143:42.

    PubMed  CAS  Google Scholar 

  13. Viscidi R, Willey S, Bartlett JG: Isolation rates and toxigenic potential for Clostridium difficile isolates from various patient populations. Gastroenterology 1981, 81:5.

    PubMed  CAS  Google Scholar 

  14. McFarlan LV, Mulligan ME, Kwok RYY, Stamm WE: Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989, 320:204.

    Article  Google Scholar 

  15. Bartlett JG: Antimicrobial agents implicated in Clostridium difficile toxin-associated diarrhea or colitis. Johns Hopkins Med J 1981, 149:6–9.

    PubMed  CAS  Google Scholar 

  16. Mylonakis E, Ryan ET, Calderwood SB: Clostridium difficileassociated diarrhea: a review. Arch Intern Med 2000, 161:523–533.

    Google Scholar 

  17. Kyne L, Warny M, Qamar A, Kelly CP: Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000, 342:390–397. The authors show that clinical expression of C. difficile with diarrhea and colitis was strongly correlated with the absence of IgG to C. difficile toxin A. This presumably explains why some patients have florid diarrhea and others have asymptomatic carriage of C. difficile toxins.

    Article  PubMed  CAS  Google Scholar 

  18. Kyne L, Warny M, Qamar A, Kelly CP: Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001, 357:189–193. The authors of reference 17 extend their observations to show that absence of toxin IgG also explains at least some relapses.

    Article  PubMed  CAS  Google Scholar 

  19. Wistrom J, Norrby SR, Myhre EB, et al.: Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: A prospective study. J Antimicrob Chemother 2001, 47:43–50. A reminder that there are many causes of nosocomial diarrhea besides antibiotics and C. difficile.

    Article  PubMed  CAS  Google Scholar 

  20. Sparks SG, Carman RJ, Sarker MR, McClane BA: Genotyping of enterotoxigenic Clostridium perfringens fecal isolates associated with antibiotic-associated diarrhea and food poisoning in North America. J Clin Microbiol 2001, 39:883–888. Clostridium perfringens may be an important cause of antibioticassociated diarrhea, but the clinician will never know because laboratories don’t test for it.

    Article  PubMed  CAS  Google Scholar 

  21. Sun M: In search of Salmonella’s smoking gun. Science 1984, 226:30–32.

    Article  PubMed  CAS  Google Scholar 

  22. Olsen SJ, DeBess EE, McGivern TE, et al.: A nosocomial outbreak of fluoroquinolone-resistant salmonella infection. N Engl J Med 2001, 334:1572–1579.

    Article  Google Scholar 

  23. Jacobs A, Barnard K, Fishel R, Gradon JD: Extracolonic manifestations of Clostridium difficile infections. Medicine 2001, 80:88–101. Clostridium difficile may cause disease outside the colon, but it is rare. This report shows seven reported cases of enteritis, which emphasizes that C. difficile in both people and hamsters causes mucosal inflammation that is sharply restricted to the colon.

    Article  PubMed  CAS  Google Scholar 

  24. Forbes D, Ee L, Camer-Pesci P, Ward PB: Faecal candida and diarrhoea. Arch Dis Child 2001, 84:328–331.

    Article  PubMed  CAS  Google Scholar 

  25. Gustafsson A, Berstad A, Lund-Tonnesen S, et al.: The effect of faecal enema on five microflora-associated characteristics in patients with antibiotic-associated diarrhoea. Scand J Gastroenterol 1999, 34:580–586.

    Article  PubMed  CAS  Google Scholar 

  26. Wanahita A, Goldsmith EA, Musher DM: Conditions associated with leukocytosis in a tertiary care hospital with particular attention to the role of infection caused by Clostridium difficile. Clin Infect Dis 2002, 34:1585–1592. The authors point out that leukocytosis is a common feature of C. difficile infection. They also note in the discussion that a new prospective study shows that C. difficile accounts for about 50% of cases of unexplained leukocytosis.

    Article  PubMed  Google Scholar 

  27. Finney JMT: Gastro-enterostomy for cicatrizing ulcer of the pylorus. Bull Johns Hopkins Hosp 1893, 4:53.

    Google Scholar 

  28. Laughon BE, Viscidi RP, Gdovin SL, et al.: Enzyme immunoassays for detection of Clostridium difficile toxins A and B in fecal specimens. J Infect Dis 1984, 149:781–788.

    PubMed  CAS  Google Scholar 

  29. Lozniewski A, Rabaud C, Dotto E, et al.: Laboratory diagnosis of Clostridium difficile-associated diarrhea and colitis: usefulness of premier cytoclone A+B enzyme immunoassay for combined detection of stool toxins and toxigenic C. difficile strains. J Clin Microbiol 2001, 39:1996–1998.

    Article  PubMed  CAS  Google Scholar 

  30. Barbut F, Kajzer C, Planas N, Petit J-C: Comparison of three enzyme immunoassays, a cytotoxicity assay, and toxigenic culture for diagnosis of Clostridium difficile-associated diarrhea. J Clin Microbiol 1993, 31:963–967.

    PubMed  CAS  Google Scholar 

  31. Gerding DN, Johnson S, Peterson LR, et al.: Clostridium difficileassociated diarrhea and colitis. Infect Control Hosp Epidemiol 1995, 16:459–477.

    Article  PubMed  CAS  Google Scholar 

  32. Bauer TM, Lalvani A, Fehrenbach J, et al.: Derivation and validation of guidelines for stool cultures for enteropathogenic bacteria other than Clostridium difficile in hospitalized adults. JAMA 2001, 285:313–319. The general rule is that C. difficile is the only frequent microbial cause of nosocomial diarrhea. Therefore, many laboratories prefer to do only the C. difficile toxin assay on these cases; cultures and ova and parasite examinations are consequently reserved for selected categories of patients.

    Article  PubMed  CAS  Google Scholar 

  33. Manabe YC, Vinetz JM, Moore RD, et al.: Clostridium difficile colitis: An efficient clinical approach to diagnosis. Ann Intern Med 1995, 123:835–840.

    PubMed  CAS  Google Scholar 

  34. Guerrant RL: Practice guidelines for the management of infectious diarrhea. Clin Infect Dis 2001, 32:331–351.

    Article  PubMed  CAS  Google Scholar 

  35. Recommendations for preventing the spread of vancomycin resistance: Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Morb Mortal Wkly Rep 1995, 44(RR-12):1–13.

    Google Scholar 

  36. Pelaez T, Alcola L, Alonso R, et al.: Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother 2002, 46:1647–1650. The authors review in vitro sensitivity data for 415 isolates of C. difficile and show 6% were resistant to metronidazole at 16 µg/mL. Relevance is unclear because it depends on colonic lumen levels.

    Article  PubMed  CAS  Google Scholar 

  37. Wenisch C, Parschalk B, Hasenhundl M, et al.: Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996, 22:813–818.

    PubMed  CAS  Google Scholar 

  38. Bartlett JG: Treatment of Clostridium difficile colitis. Gastroenterology 1985, 89:1192–1195.

    PubMed  CAS  Google Scholar 

  39. McFarland LV, Surawicz CM, Greenberg RN, et al.: A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994, 271:1913–1918.

    Article  PubMed  CAS  Google Scholar 

  40. McFarland LV, Surawicz CM, Rubin M, et al.: Recurrent Clostridium difficile disease: Epidemiology and clinical characteristics. Infect Control Hosp Epidemiol 1999, 20:43–50.

    Article  PubMed  CAS  Google Scholar 

  41. Gorbach S, Chang T-W, Goldin B: Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG. Lancet 1987, 2:1519.

    Article  PubMed  CAS  Google Scholar 

  42. Salcedo J, Keates S, Pothoulakis C, et al.: Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut 1997, 41:366–370.

    Article  PubMed  CAS  Google Scholar 

  43. Schwan A, Sjolin S, Trottestam U, Aronsson B: Relapsing Clostridium difficile enterocolitis cured by rectal infusion of normal faeces. Scand J Infect Dis 1984, 16:211–215.

    Article  PubMed  CAS  Google Scholar 

  44. Johnson S, Samore MH, Farrow KA, et al.: Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. N Engl J Med 1999, 341:1645–1651. One of several reports showing the importance of controlling clindamycin use in nosocomial epidemics of C. difficile-associated diarrhea.

    Article  PubMed  CAS  Google Scholar 

  45. Climo MW, Israel DS, Wong ES, et al.: Hospital-wide restriction of clindamycin: Effect on the incidence of Clostridium difficile-associated diarrhea and cost. Ann Intern Med 1998, 128:989–995.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Johns Hopkins University School of Medicine, 1830 E. Monument Street, Room 437, 21287-0003, Baltimore, MD, USA

    John G. Bartlett MD

Authors
  1. John G. Bartlett MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bartlett, J.G. Clostridium difficile-associated enteric disease. Curr Infect Dis Rep 4, 477–483 (2002). https://doi.org/10.1007/s11908-002-0032-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11908-002-0032-0

Keywords

Search

Navigation